熱門資訊> 正文
艾伯维获得欧盟批准Rinvoq治疗儿科关节炎
2026-09-22 14:30
- AbbVie (ABBV) on Tuesday said that Rinvoq is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs.
- Rinvoq may be used as monotherapy or in combination with methotrexate, the company said.
- The approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis. A new oral solution of Rinvoq was approved for use in patients with pJIA, AbbVie (ABBV) said.
- Rinvoq is currently approved in the European Union for 11 indications across various immune-mediated inflammatory diseases.
More on AbbVie
- AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
- AbbVie inks multi-year AI drug discovery deal with Iambic Therapeutics
- Trump announces MFN pricing for Medicaid in all states
推薦文章
美股前瞻 | 霍爾木茲海峽或7天內重開！國際油價齊挫，三大期指轉升；美聯儲「二把手」今夜發言；阿里雲棲大會加碼AI基建及自研芯片
Meta點燃半導體、CPU「超級行情」！英特爾年內勁升超230%，AI硬件還有哪些標的獲看好？
華盛早報 | 兩大利好引爆芯片股！英特爾大漲12%，AMD市值破萬億美元；Muse智能體助推Meta飆升11%；阿里雲棲大會今日開幕
美股前瞻 | 中美高層會談釋放積極信號！納指期貨升逾1%；比特幣再度站上8.5萬美元；英特爾盤前升逾5%，佈局先進封裝劍指光通信賽道
新股申購 | 四隻新股今起招股！PCB龍頭景旺電子、直驅機器人公司本末科技、羅博特科、彤程新材在列
港股異動 | 創新葯概念集體走高，英派藥業-B飆漲逾27%，榮昌生物、康方生物、信達生物漲逾6%，藥明生物漲逾5%
華盛早報 | 中美經貿磋商正在紐約進行！特朗普引爆資源股！GLND夜盤飆升119%；景旺電子等四隻新股今起招股
港股周報 | 加息落地！科技股企穩反彈，恆生科指漲近2%；利潤率比肩戴爾？聯想周漲20%再創新高
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
